公开(公告)号：WO2011123674A1

公开(公告)日：2011-10-06

申请号：PCT/US2011/030769

申请日：2011-03-31

Applicant: ARRAY BIOPHARMA INC. ,  GENENTECH, INC. ,  CLARK, Christopher, T. ,  COOK, Adam ,  GUNAWARDANA, Indrani, W. ,  HUNT, Kevin W. ,  KALLAN, Nicholas, C. ,  SIU, Michael ,  THOMAS, Allen, A. ,  VOLGRAF, Matthew

Inventor： CLARK, Christopher, T. ,  COOK, Adam ,  GUNAWARDANA, Indrani, W. ,  HUNT, Kevin W. ,  KALLAN, Nicholas, C. ,  SIU, Michael ,  THOMAS, Allen, A. ,  VOLGRAF, Matthew

IPC: C07D401/10 ,  C07D401/14 ,  C07D403/10 ,  C07D413/10 ,  C07D417/10 ,  C07D263/64 ,  A61K31/41 ,  A61P25/28

CPC classification number: C07D401/14 ,  C07D263/64 ,  C07D401/10 ,  C07D403/10 ,  C07D413/10 ,  C07D417/10

Abstract: The invention provides novel spirotetrahydronaphthalene compounds of Formula α that inhibit β-secretase cleavage of APP and are useful as therapeutic agents for treating neurodegenerative diseases.

Abstract translation: 本发明提供新颖的抑制APP分泌​​酶切割的式（a）的四氢四氢化合物，可用作治疗神经变性疾病的治疗剂。

公开(公告)号：WO2009158426A1

公开(公告)日：2009-12-30

申请号：PCT/US2009/048499

申请日：2009-06-24

Applicant: ARRAY BIOPHARMA INC. ,  BURGESS, Laurence, E. ,  CLARK, Christopher, T. ,  COOK, Adam ,  CORRETTE, Christopher, P. ,  DELISLE, Robert, Kirk ,  DOHERTY, George, A. ,  HUNT, Kevin, W. ,  ROMOFF, Todd

Inventor： BURGESS, Laurence, E. ,  CLARK, Christopher, T. ,  COOK, Adam ,  CORRETTE, Christopher, P. ,  DELISLE, Robert, Kirk ,  DOHERTY, George, A. ,  HUNT, Kevin, W. ,  ROMOFF, Todd

IPC: C07D311/04 ,  C07D405/12 ,  C07D407/12 ,  A61K31/353 ,  A61P29/00

CPC classification number: C07D311/58 ,  C07D311/04 ,  C07D405/12 ,  C07D407/12

Abstract: Compounds of Formula (I): in which A 1 , A 2 , W, L, G, R 7a , R 7b , R 8 , R 9 and R 10 have the meanings given in the specification, are DP2 receptor modulators useful in the treatment of immunologic diseases.

Abstract translation: 式（I）化合物：其中A1，A2，W，L，G，R7a，R7b，R8，R9和R10具有本说明书中给出的含义，是可用于治疗免疫疾病的DP2受体调节剂。

公开(公告)号：WO2007126871A1

公开(公告)日：2007-11-08

申请号：PCT/US2007/007658

申请日：2007-03-27

Applicant: ARRAY BIOPHARMA INC. ,  MUNSON, Mark ,  HUNT, Kevin, W. ,  CLARK, Christopher, T. ,  KIM, Ganghyeok ,  BURGESS, Laurence, E. ,  RIZZI, James

Inventor： MUNSON, Mark ,  HUNT, Kevin, W. ,  CLARK, Christopher, T. ,  KIM, Ganghyeok ,  BURGESS, Laurence, E. ,  RIZZI, James

IPC: C07D403/12 ,  C07D401/12 ,  A61K31/416 ,  A61P29/00

CPC classification number: C07D403/12 ,  C07D401/12

Abstract: Compounds of formula (I): in which A, B, X, Ar 1 , R 8 and R 4 have any of the meanings given in the specification, are inhibitors of p38 useful in the treatment and prevention of various disorders mediated by p38.

Abstract translation: 式（I）化合物：其中A，B，X，Ar 1，R 8和R 4具有给定的任何含义 在说明书中是p38的抑制剂，其可用于治疗和预防由p38介导的各种疾病。

公开(公告)号：WO2010075200A1

公开(公告)日：2010-07-01

申请号：PCT/US2009/068672

申请日：2009-12-18

Applicant: ARRAY BIOPHARMA INC. ,  COOK, Adam ,  HUNT, Kevin, W. ,  DELISLE, Robert Kirk ,  ROMOFF, Todd ,  CLARK, Christopher, T. ,  KIM, Ganghyeok ,  CORRETTE, Christopher, P. ,  DOHERTY, George, A. ,  BURGESS, Laurence, E.

Inventor： COOK, Adam ,  HUNT, Kevin, W. ,  DELISLE, Robert Kirk ,  ROMOFF, Todd ,  CLARK, Christopher, T. ,  KIM, Ganghyeok ,  CORRETTE, Christopher, P. ,  DOHERTY, George, A. ,  BURGESS, Laurence, E.

IPC: C07D405/12 ,  C07D405/14 ,  C07D413/12 ,  C07D417/12 ,  A61K31/353 ,  A61P29/00

CPC classification number: C07D405/12 ,  C07D405/14 ,  C07D413/12 ,  C07D417/12

Abstract: Compounds of Formula I: (I) in which A, A 1 , R 1 , R 7a , R 7b , R 8 and R 10 have the meanings given in the specification, are DP2 receptor inhibitors useful in the treatment of useful in the treatment and prevention of immunologic diseases, allergic diseases such as asthma, allergic rhinitis and atopic dermatitis, and other inflammatory diseases mediated by prostaglandin D 2 (PGD 2 ). The compounds of Formula I may also be useful in treating diseases or medical conditions involving the Th2 T cell via production of IL-4, IL-5 and/or IL-13.

Abstract translation: 其中A，A1，R1，R7a，R7b，R8和R10具有本说明书中给出的含义的式I化合物：（I）是可用于治疗和预防免疫疾病的DP2受体抑制剂， 过敏性疾病如哮喘，过敏性鼻炎和特应性皮炎，以及由前列腺素D2（PGD2）介导的其他炎性疾病。 式I化合物还可用于通过产生IL-4，IL-5和/或IL-13来治疗涉及Th2T细胞的疾病或医学病症。